Menu Search
Equities

Integra Lifesciences Holdings Corp

IART:NSQ

Integra Lifesciences Holdings Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)17.47
  • Today's Change-0.06 / -0.34%
  • Shares traded798.09k
  • 1 Year change-55.51%
  • Beta1.0973
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform2
Hold6
Sell3
Strong Sell2

Share price forecast in USD

The 9 analysts offering 12 month price targets for Integra Lifesciences Holdings Corp have a median target of 26.00, with a high estimate of 40.00 and a low estimate of 20.00. The median estimate represents a 48.83% increase from the last price of 17.47.
High129.0%40.00
Med48.8%26.00
Low14.5%20.00

Earnings history & estimates in USD

On Jul 29, 2024, Integra Lifesciences Holdings Corp reported 2nd quarter 2024 earnings of 0.63 per share. This result was in line with the consensus of the 11 analysts following the company and under-performed last year's 2nd quarter results by 11.27%.
The next earnings announcement is expected on Oct 23, 2024.
Average growth rate+0.12%
Integra Lifesciences Holdings Corp reported annual 2023 earnings of 3.10 per share on Feb 28, 2024.
Average growth rate+4.28%
More ▼

Revenue history & estimates in USD

Integra LifeSciences Holdings Corporation had 2nd quarter 2024 revenues of 418.18m. This bettered the 413.15m consensus of the 10 analysts covering the company. This was 9.80% above the prior year's 2nd quarter results.
Average growth rate+2.60%
Integra LifeSciences Holdings Corporation had revenues for the full year 2023 of 1.54bn. This was 1.03% below the prior year's results.
Average growth rate+0.70%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.